On 1 December 2017, 12Sigma announced the completion of its Series B financing with a total amount of approximately RMB200 million, which is the largest single equity financing in the medical imaging AI field in 2017 with leading investor Softbank China Venture Capital (SBCVC), together with other investors (i.e. CDBI Partner and Delian Capital). 12 Simga's existing investors Zhen Fund and Matrix Partners China participated in this round as well.
12Sigma, a system developer dedicated to lead deep learning artificial intelligence technology into medical diagnostic, was founded in April 2015. 12Sigma aims to research and develop the automatic medical diagnosis system and medical data analysis system based on deep learning technology. 12Sigma possesses cutting-edge technologies of in-depth studying. Its products are all in the leading positions compared to similar products in areas of artificial intelligence detection of pulmonary nodules, automatic lesion segmentation, benign and malignant analysis, image extraction, periodic follow-up function for pulmonary nodules and etc. The Series B financing will help to reinforce 12sigma's AI research team and marketing team with the aim of further development and promotion of the product line.
Acting as the legal counsel of SBCVC, we provided legal services in respect of legal due diligence, documentation review and negotiations, coordination with all parties, assistance in closing matters.
